Literature DB >> 12124776

Exendin-4 differentiation of a human pancreatic duct cell line into endocrine cells: involvement of PDX-1 and HNF3beta transcription factors.

Jie Zhou1, Marco A Pineyro, Xiaolin Wang, Maire E Doyle, Josephine M Egan.   

Abstract

Exendin-4 (EX-4), a long acting agonist of GLP-1, induces an endocrine phenotype in Capan-1 cells. Under culture conditions which include serum, approximately 10% of the cells contain insulin and glucagon. When exposed to EX-4 (0.1 nM, up to 5 days), the number of cells containing insulin and glucagon increased to approximately 40%. Western blot analysis detected a progressive increase in protein levels of glucokinase and GLUT2 over 3 days of EX-4 treatment. We explored the sequence of activation of certain transcription factors known to be essential for the beta cell phenotype: PDX-1, Beta2/NeuroD, and hepatocyte nuclear factor 3beta (HNF3beta). Double immunostaining showed that PDX-1 coexisted with insulin and glucagon in EX-4-treated cells. Treatment caused an increase in PDX-1 protein levels by 24 h and induced its nuclear translocation. Beta2/NeuroD protein levels also increased progressively over 24 h. HNF3beta protein level increased twofold as early as 6 h after EX-4 treatment. EMSA results indicated that EX-4 caused a 12-fold increase in HNF3beta binding to PDX-1 promoter area II. Beta2/NeuroD protein levels progressively increased after 24 h treatment. Differentiation to insulin-producing cells was also seen when Capan-1 cells were transfected with pdx-1, with 80% of these cells expressing insulin 3 days after transfection. PDX-1 antisense totally inhibited such conversion. During the differentiation of duct cells to endocrine cells, cAMP levels (EX-4 is a ligand for the GLP-1, G-protein coupled receptor) and MAP kinase activity increased. Our results indicate that EX-4 activates adenylyl cyclase and MAP kinase which, in turn, may lead to activation of transcription factors necessary for an endocrine phenotype. Published 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12124776     DOI: 10.1002/jcp.10143

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  25 in total

Review 1.  Stem cell therapy for type 1 diabetes mellitus.

Authors:  Cristina Aguayo-Mazzucato; Susan Bonner-Weir
Journal:  Nat Rev Endocrinol       Date:  2010-03       Impact factor: 43.330

2.  Glucagon-like peptide-1 receptor agonist exendin-4 protects against interleukin-1β-mediated inhibition of glucose-stimulated insulin secretion by mouse insulinoma β cells.

Authors:  Ben Niu; Chao Li; Heng Su; Qingzhu Li; Qiu He; Lijuan Liu; Yuanming Xue; Tao Shen; Xueshan Xia
Journal:  Exp Ther Med       Date:  2017-07-19       Impact factor: 2.447

Review 3.  Switching cell fate: the remarkable rise of induced pluripotent stem cells and lineage reprogramming technologies.

Authors:  Vimal Selvaraj; Jennifer M Plane; Ambrose J Williams; Wenbin Deng
Journal:  Trends Biotechnol       Date:  2010-02-09       Impact factor: 19.536

4.  Prophylactic effects of the glucagon-like Peptide-1 analog liraglutide on hyperglycemia in a rat model of type 2 diabetes mellitus associated with chronic pancreatitis and obesity.

Authors:  Dai Nagakubo; Mitsuyuki Shirai; Yuki Nakamura; Noriyuki Kaji; Chika Arisato; Sena Watanabe; Ayami Takasugi; Fumitoshi Asai
Journal:  Comp Med       Date:  2014-04       Impact factor: 0.982

Review 5.  The role of incretins in glucose homeostasis and diabetes treatment.

Authors:  Wook Kim; Josephine M Egan
Journal:  Pharmacol Rev       Date:  2008-12-12       Impact factor: 25.468

6.  Incretin mimetics as pharmacologic tools to elucidate and as a new drug strategy to treat traumatic brain injury.

Authors:  Nigel H Greig; David Tweedie; Lital Rachmany; Yazhou Li; Vardit Rubovitch; Shaul Schreiber; Yung-Hsiao Chiang; Barry J Hoffer; Jonathan Miller; Debomoy K Lahiri; Kumar Sambamurti; Robert E Becker; Chaim G Pick
Journal:  Alzheimers Dement       Date:  2014-02       Impact factor: 21.566

Review 7.  Regenerating pancreatic beta-cells: plasticity of adult pancreatic cells and the feasibility of in-vivo neogenesis.

Authors:  Kirstine Juhl; Susan Bonner-Weir; Arun Sharma
Journal:  Curr Opin Organ Transplant       Date:  2010-02       Impact factor: 2.640

Review 8.  β-cell replacement sources for type 1 diabetes: a focus on pancreatic ductal cells.

Authors:  Elisa Corritore; Yong-Syu Lee; Etienne M Sokal; Philippe A Lysy
Journal:  Ther Adv Endocrinol Metab       Date:  2016-06-06       Impact factor: 3.565

Review 9.  A feat of metabolic proportions: Pdx1 orchestrates islet development and function in the maintenance of glucose homeostasis.

Authors:  Daniella A Babu; Tye G Deering; Raghavendra G Mirmira
Journal:  Mol Genet Metab       Date:  2007-07-30       Impact factor: 4.797

Review 10.  Slow and steady is the key to beta-cell replication.

Authors:  Kristen Brennand; Doug Melton
Journal:  J Cell Mol Med       Date:  2009-03       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.